Tag
Resistance exercise induces prolonged increases in glutamate production in older adults with COPD and healthy controls, highlighting unique metabolic adaptations that may influence pulmonary rehabilitation outcomes and muscle health.
The BREATHE trial reveals that novel self-expanding nitinol airway scaffolds are safe, feasible, and effective in reducing lung hyperinflation and improving symptoms in severe emphysema patients at six months post-implantation.
The FRONTIER-4 phase 2a trial evaluated tozorakimab, an anti-IL-33 monoclonal antibody, in moderate-to-severe COPD with chronic bronchitis. While the primary endpoint was unmet in the overall population, efficacy signals emerged in patients
This study reveals how thoracoabdominal asynchrony (TAA) during exercise reflects lung function severity and predicts breathlessness in very severe COPD patients, highlighting its potential to guide personalized respiratory support strategi
A large phase 4 trial found carbocysteine did not significantly reduce exacerbation rates or improve lung function in mild-to-moderate COPD, suggesting limited benefit beyond severe cases.
Nasal high flow therapy modestly improves tidal volume and dyspnoea during exercise in severe COPD but has minimal effect on respiratory muscle workload or endurance capacity.
AI decision support significantly improves primary care clinicians’ accuracy in spirometry diagnosis, especially for COPD, addressing a key gap in respiratory disease management.
COPD in adults under 50 affects 4.5% of this population and is linked to increased risks of early mortality and serious cardiopulmonary events, underscoring the need for early identification and intervention.
Dupilumab significantly reduced type 2 inflammation biomarkers and exacerbation risk in COPD patients with elevated eosinophils, highlighting the value of biomarker-driven therapy.
